A. Jonville-béra, M. Mallaret, and C. Sgro, Association française des Centres régionaux de pharmacovigilance, pp.351-355, 2016.

J. Faillie, F. Montastruc, J. Montastruc, and A. Pariente, L???apport de la pharmaco-??pid??miologie ?? la pharmacovigilance, Th??rapie, vol.71, issue.2, pp.203-212, 2016.
DOI : 10.1016/j.therap.2016.02.015

J. Horn and P. Hansten, Careful Scrutiny of the Evidence for Drug-Drug Interactions in Clinical Decision Support Systems Is Necessary, Journal of Managed Care Pharmacy, vol.17, issue.9, p.713, 2011.
DOI : 10.18553/jmcp.2011.17.9.713

G. Brophy, Stockley??s Drug Interactions, Critical Care Medicine, vol.34, issue.11, p.2873, 2006.
DOI : 10.1097/01.CCM.0000243724.78879.8F

D. Levêque, J. Lemachatti, Y. Nivoix, P. Coliat, R. Santucci et al., M??canismes des interactions m??dicamenteuses d???origine pharmacocin??tique, La Revue de M??decine Interne, vol.31, issue.2, pp.170-179, 2010.
DOI : 10.1016/j.revmed.2009.07.009

P. Médicale and . Internet, [cité 16 sept 2017] Disponible sur: https://pharmacomedicale.org/index.php?option=com_content&view=article&id=102:variations- du-metabolisme-hepatique-des-medicaments&catid=45&Itemid=301

F. Girardin, Membrane transporter proteins: a challenge for CNS drug development, Dialogues Clin Neurosci, vol.8, issue.3, pp.311-332, 2006.

S. Nigam, What do drug transporters really do?, Nature Reviews Drug Discovery, vol.12, issue.1, pp.29-44, 2015.
DOI : 10.1002/ibd.20849

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750486/pdf

B. Diquet and C. Soubrie, Pharmacocin??tique et m??tabolisme des m??dicaments, EMC - Trait?? de m??decine AKOS, vol.1, issue.1, pp.1-6, 1998.
DOI : 10.1016/S1634-6939(06)75132-8

C. Dupeux, B. Guillet, E. Sampol-manos, L. Viard, A. Durand et al., Interaction ciclosporinecisapride chez une patiente transplantée pulmonaire, J Pharm Clin. 12 févr, vol.21, issue.4, pp.291-294, 2003.

/. Thériaque-amiodarone and . Dabigatran, Disponible sur: http://www.theriaque.org/apps/interaction/itr_interaction.php 23, 2017.

P. Breedveld, D. Pluim, G. Cipriani, P. Wielinga, O. Tellingen et al., Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients, Cancer Research, vol.65, issue.7, pp.2577-82, 2005.
DOI : 10.1158/0008-5472.CAN-04-2416

. Thériaque-carbamazepine, Progestatif contraceptif [Internet]. [cité 16 sept 2017, Disponible sur

F. Raffi, Optimisation de l???efficacit?? des inhibiteurs de prot??ase par ????boosting????, M??decine et Maladies Infectieuses, vol.33, issue.S2, pp.111-117, 2003.
DOI : 10.1016/S0399-077X(02)00477-8

A. Blanchard, R. Poussou, and P. Houillier, Exploration des fonctions tubulaires r??nales, N??phrologie & Th??rapeutique, vol.5, issue.1, pp.68-83, 2009.
DOI : 10.1016/j.nephro.2008.03.004

/. Thériaque-levodopa and . Metoclopramide, Disponible sur: http://www.theriaque.org/apps/interaction/itr_interaction.php 37. VIDAL - Naloxone [Internet]. [cité 16 sept 2017]. Disponible sur: https://www.vidal.fr/substances, 38. Interactions médicamenteuses -ANSM [Internet]. [cité 16 sept 2017]. Disponible sur, 2017.

A. Vitry, Comparative assessment of four drug interaction compendia, British Journal of Clinical Pharmacology, vol.41, issue.6, pp.709-723, 2007.
DOI : 10.1331/154434504773062573

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2006.02809.x/pdf

L. Cinq and «. Trop, des essais clinique : un plaidoyer pour une pharmacoépidémiologie pour tous

J. Caron, M. Rochoy, L. Gaboriau, and S. Gautier, Histoire de la pharmacovigilance, Th??rapie, vol.71, issue.2, pp.123-131, 2016.
DOI : 10.1016/j.therap.2016.02.026

T. Vial, Pharmacovigilance fran??aise??: missions, organisation et perspectives, Th??rapie, vol.71, issue.2, pp.135-177, 2016.
DOI : 10.1016/j.therap.2016.02.028

R. Benkirane, Les effets indésirables des médicaments [Internet]. [cité 9 juill 2016]. Disponible sur

L. Organisation-mondiale-de and . Santé, Pharmacovigilance : assurer la sécurité d'emploi des médicaments [Internet], Disponible sur, 2004.

M. Laroche, A. Batz, H. Géniaux, C. Féchant, L. Merle et al., La pharmacovigilance europ??enne??: place du Comit?? pour l?????valuation des risques en mati??re de pharmacovigilance (Pharmacovigilance Risk Assessment Committee???????PRAC) dans l???organisation et le processus d??cisionnel, Th??rapie, vol.71, issue.2, pp.151-60, 2016.
DOI : 10.1016/j.therap.2015.10.001

F. Montastruc, A. Palmaro, H. Bagheri, L. Schmitt, J. Montastruc et al., Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase, European Neuropsychopharmacology, vol.25, issue.10, pp.1556-65, 2015.
DOI : 10.1016/j.euroneuro.2015.07.010

G. Miremont-salamé, H. Théophile, F. Haramburu, and B. Bégaud, Imputabilit?? en pharmacovigilance??: de la m??thode fran??aise originelle aux m??thodes r??actualis??es, Th??rapie, vol.71, issue.2, pp.171-179, 2016.
DOI : 10.1016/j.therap.2016.02.009

J. Montastruc, A. Sommet, I. Lacroix, P. Olivier, G. Durrieu et al., La pharmacovigilance et??l'??valuation du??risque m??dicamenteux: int??r??t, fonctionnement et??m??thodes, Revue du Rhumatisme, vol.73, issue.10-11, pp.10-111021, 2006.
DOI : 10.1016/j.rhum.2006.09.008

S. Bencheikh and R. , Généralités sur la notification spontanée : quoi, qui, pourquoi, comment, quand, où ?

G. Ansm-présentation, Disponible sur: http://www.ansm.sante.fr/var/ansm_site/storage/original/application/e40e2860ec6fe38f8708cfda ab704b65.pdf 57. Health care in the elderly: report of the Technical Group on Use of Medicaments by the Elderly, World Health Organization. Drugs. oct, vol.22, issue.4, pp.279-94, 1981.

J. Laporte, Connaissance des effets indésirables des médicaments : pour une pharmacovigilance plus ambitieuse

M. Monégat and C. Sermet, La polymédication : définitions, mesures et enjeux. Questions d'économie de la santé, pp.1-8, 2014.

É. Amar and C. Pereira, Les prescriptions des médecins généralistes et leurs déterminants, Etudes Résultats, issue.440, pp.1-12, 2005.

S. Chambaretaud, La consommation de médicaments dans les principaux pays industrialisés, Etudes Résultats, issue.47, pp.1-8, 2000.

R. Scheife, L. Hines, R. Boyce, S. Chung, J. Momper et al., Consensus Recommendations for Systematic Evaluation of Drug???Drug Interaction Evidence for Clinical Decision Support, Drug Safety, vol.2, issue.3, pp.197-206, 2015.
DOI : 10.1331/154434504773062591

N. Manchon, E. Bercoff, P. Lemarchand, P. Chassagne, J. Senant et al., Fr??quence et gravit?? des interactions m??dicamenteuses dans une population ??g??e: ??tude prospective concernant 639 malades, La Revue de M??decine Interne, vol.10, issue.6, pp.515-535, 1989.
DOI : 10.1016/S0248-8663(89)80069-4

N. Rémy, M. Lapeyre-mestre, M. Bareille, H. Bagheri, and J. Montastruc, Interactions médicamenteuses : à propos d'une étude prospective pilote en médecine générale libérale, Thérapie. juin, vol.55, issue.3, pp.395-403, 2000.

L. Lay, M. Lay, J. Fournier, and J. Montastruc, Interactions médicamenteuses potentielles en médecine générale : comparaison de deux études transversales en, Thérapie, vol.68, issue.6, p.3, 1997.

R. Roubille, B. Charpiat, L. Escoffier, P. Bedouch, M. Juste et al., Potentiel d'étude de la base ACT-IP : illustration avec les interactions médicamenteuses, J Pharm Clin. 1 nov, vol.26, issue.4, pp.261-267, 2007.

R. Goldberg, J. Mabee, L. Chan, and S. Wong, Drug-drug and drug-disease interactions in the ED: Analysis of a high-risk population, The American Journal of Emergency Medicine, vol.14, issue.5, pp.447-50, 1996.
DOI : 10.1016/S0735-6757(96)90147-3

Y. Chen, A. Avery, K. Neil, C. Johnson, M. Dewey et al., Incidence and Possible Causes of Prescribing Potentially Hazardous/Contraindicated Drug Combinations in General Practice, Drug Safety, vol.45, issue.1, pp.67-80, 2005.
DOI : 10.2165/00002018-200528010-00005

R. Aparasu, R. Baer, and A. Aparasu, Clinically important potential drug-drug interactions in outpatient settings, Research in Social and Administrative Pharmacy, vol.3, issue.4, pp.426-463, 2007.
DOI : 10.1016/j.sapharm.2006.12.002

B. Glintborg, S. Andersen, and K. Dalhoff, Drug-drug interactions among recently hospitalised patients ??? frequent but mostly clinically insignificant, European Journal of Clinical Pharmacology, vol.11, issue.9, pp.675-81, 2005.
DOI : 10.1080/00325481.1992.11701373

J. Gagne, V. Maio, and C. Rabinowitz, Prevalence and predictors of potential drug???drug interactions in Regione Emilia-Romagna, Italy, Journal of Clinical Pharmacy and Therapeutics, vol.15, issue.2, pp.141-51, 2008.
DOI : 10.2165/00002018-200528050-00001

P. Vonbach, A. Dubied, S. Krähenbühl, and J. Beer, Prevalence of drug???drug interactions at hospital entry and during hospital stay of patients in internal medicine, European Journal of Internal Medicine, vol.19, issue.6, pp.413-433, 2008.
DOI : 10.1016/j.ejim.2007.12.002

J. Zwart-van-rijkom, E. Uijtendaal, T. Berg, M. Van-solinge, W. Egberts et al., Frequency and nature of drug-drug interactions in a Dutch university hospital, British Journal of Clinical Pharmacology, vol.15, issue.2, pp.187-93, 2009.
DOI : 10.1097/00003643-199803000-00009

L. Pasina, C. Djade, A. Nobili, M. Tettamanti, C. Franchi et al., Drug-drug interactions in a cohort of hospitalized elderly patients, Pharmacoepidemiology and Drug Safety, vol.22, issue.13, pp.1054-60, 2013.
DOI : 10.1016/j.jacc.2009.05.050

M. Ganeva, T. Gancheva, J. Troeva, N. Kiriyak, and E. Hristakieva, Clinical relevance of drug-drug interactions in hospitalized dermatology patients, Adv Clin Exp Med Off Organ Wroclaw Med Univ. août, vol.22, issue.4, pp.555-63, 2013.

J. Feinstein, D. Dai, W. Zhong, J. Freedman, and C. Feudtner, Potential Drug-Drug Interactions in Infant, Child, and Adolescent Patients in Children's Hospitals, PEDIATRICS, vol.135, issue.1, pp.99-108, 2015.
DOI : 10.1542/peds.2014-2015

URL : http://pediatrics.aappublications.org/content/pediatrics/135/1/e99.full.pdf

M. Ismail, Z. Iqbal, M. Khattak, M. Khan, H. Arsalan et al., Potential drug???drug interactions in internal medicine wards in hospital setting in Pakistan, International Journal of Clinical Pharmacy, vol.7, issue.3, pp.455-62, 2013.
DOI : 10.1186/1472-6963-7-147

A. Ahmad, Evaluation of Potential Drug - Drug Interactions in General Medicine Ward of Teaching Hospital in Southern India, JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, vol.9, issue.2, pp.10-13, 2015.
DOI : 10.7860/JCDR/2015/11264.5608

H. Gacem, H. Beriala, A. Hamzi, R. Derghal, and A. Ahmane, Les interactions m??dicamenteuses en clinique??: ??tude prospective ciblant un service de cardiologie, Le Pharmacien Hospitalier et Clinicien, vol.49, issue.2, pp.2-6, 2014.
DOI : 10.1016/j.phclin.2014.04.227

A. Bhagavathula, A. Berhanie, H. Tigistu, Y. Abraham, Y. Getachew et al., Prevalence of potential drug???drug interactions among internal medicine ward in University of Gondar Teaching Hospital, Ethiopia, Asian Pacific Journal of Tropical Biomedicine, vol.4, issue.S1, pp.204-212, 2014.
DOI : 10.12980/APJTB.4.2014C1172

H. Kafeel, R. Rukh, H. Qamar, J. Bawany, M. Jamshed et al., Possibility of Drug-Drug Interaction in Prescription Dispensed by Community and Hospital Pharmacy, Pharmacology & Pharmacy, vol.05, issue.04, p.5401, 2014.
DOI : 10.4236/pp.2014.54048

M. Becker, M. Kallewaard, P. Caspers, L. Visser, H. Leufkens et al., Hospitalisations and emergency department visits due to drug???drug interactions: a literature review, Pharmacoepidemiology and Drug Safety, vol.289, issue.6, pp.641-51, 2007.
DOI : 10.1111/j.1365-2125.1992.tb04001.x

T. Juárez-cedillo, C. Martinez-hernández, A. Hernández-constantino, J. Garcia-cruz, A. Avalos-mejia et al., Clinical Weighting of Drug-Drug Interactions in Hospitalized Elderly, Basic & Clinical Pharmacology & Toxicology, vol.114, issue.37 Pt 2, pp.298-305, 2016.
DOI : 10.1111/bcpt.12185

A. Marengoni, L. Pasina, C. Concoreggi, G. Martini, F. Brognoli et al., Understanding adverse drug reactions in older adults through drug???drug interactions, European Journal of Internal Medicine, vol.25, issue.9, pp.843-849, 2014.
DOI : 10.1016/j.ejim.2014.10.001

A. Bénard-laribière, G. Miremont-salamé, M. Pérault-pochat, P. Noize, and F. Haramburu, Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study, Fundamental & Clinical Pharmacology, vol.88, issue.1, pp.106-117, 2015.
DOI : 10.1016/j.mayocp.2013.03.006

A. Danton, F. Montastruc, A. Sommet, G. Durrieu, H. Bagheri et al., Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug???drug interactions: a PharmacoVigilance study in France, European Journal of Clinical Pharmacology, vol.11, issue.4, pp.885-893, 2013.
DOI : 10.1517/14740338.2012.631910

C. Buc?a, A. Farca?, I. Cazacu, D. Leucuta, A. Achimas-cadariu et al., How many potential drug???drug interactions cause adverse drug reactions in hospitalized patients?, European Journal of Internal Medicine, vol.24, issue.1, pp.27-33, 2013.
DOI : 10.1016/j.ejim.2012.09.011

S. Marusic, V. Bacic-vrca, O. Neto, P. Franic, M. Erdeljic et al., Actual drug???drug interactions in elderly patients discharged from internal medicine clinic: a prospective observational study, European Journal of Clinical Pharmacology, vol.61, issue.9, pp.1717-1741, 2013.
DOI : 10.1007/s11096-008-9191-x

O. Neto, P. Nobili, A. De-lyra, D. Pilger, D. Guidoni et al., Incidence and predictors of adverse drug reactions caused by drug-drug interactions in elderly outpatients: a prospective cohort study, J Pharm Pharm Sci Publ Can Soc Pharm Sci Soc Can Sci Pharm, vol.15, issue.2, pp.332-375, 2012.

J. Strandell and S. Wahlin, Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database, European Journal of Clinical Pharmacology, vol.24, issue.1, pp.633-674, 2011.
DOI : 10.1097/00007691-200202000-00016

URL : https://hal.archives-ouvertes.fr/hal-00661924

R. Leone, L. Magro, U. Moretti, P. Cutroneo, M. Moschini et al., Identifying Adverse Drug Reactions Associated with Drug-Drug Interactions, Drug Safety, vol.76, issue.8, pp.667-75, 2010.
DOI : 10.1111/j.1532-5415.1996.tb01865.x

M. Skvrce, N. , M. Sarinic, V. Mucalo, I. Krnic et al., Adverse drug reactions caused by drug-drug interactions reported to Croatian Agency for Medicinal Products and Medical Devices: a retrospective observational study, Croatian Medical Journal, vol.52, issue.5, pp.604-618, 2011.
DOI : 10.3325/cmj.2011.52.604

A. Reis and S. Cassiani, Adverse drug events in an intensive care unit of a university hospital, European Journal of Clinical Pharmacology, vol.39, issue.7???8, pp.625-657, 2011.
DOI : 10.1345/aph.1E642

A. Farcas, A. Sinpetrean, C. Mogosan, M. Palage, O. Vostinaru et al., Adverse drug reactions detected by stimulated spontaneous reporting in an internal medicine department in Romania, European Journal of Internal Medicine, vol.21, issue.5, pp.453-460, 2010.
DOI : 10.1016/j.ejim.2010.05.014

J. Schuler, C. Dückelmann, W. Beindl, E. Prinz, T. Michalski et al., Polypharmakotherapie und unangemessene Verschreibung bei ??lteren internistischen Patienten in ??sterreich, Wiener klinische Wochenschrift, vol.55, issue.23-24, pp.23-24733, 2008.
DOI : 10.7326/0003-4819-147-11-200712040-00006

L. Tulner, S. Frankfort, G. Gijsen, J. Van-campen, C. Koks et al., Drug-Drug Interactions in a Geriatric Outpatient Cohort, Drugs & Aging, vol.143, issue.2, pp.343-55, 2008.
DOI : 10.1007/BF03083579

J. Strandell, A. Bate, M. Lindquist, I. Edwards, and F. Swedish, Drug-drug interactions - a preventable patient safety issue?, British Journal of Clinical Pharmacology, vol.28, issue.Suppl. 1, pp.144-150, 2008.
DOI : 10.1111/j.1365-2125.2007.02981.x

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2007.02981.x/pdf

J. Cruciol-souza and J. Thomson, A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital, Clinics, vol.61, issue.6, pp.515-535, 2006.
DOI : 10.1590/S1807-59322006000600005

F. Caraci, S. Enna, J. Zohar, G. Racagni, G. Zalsman et al., A new nomenclature for classifying psychotropic drugs, British Journal of Clinical Pharmacology, vol.172, issue.8, pp.1614-1620, 2017.
DOI : 10.1111/bph.13347

A. Les-anticoagulants-en-france-en, état des lieux, synthèse et surveillance : rapport [Internet]. 2014 [cité 17 sept 2017]. Disponible sur: http://ansm.sante.fr/Dossiers/Lesanticoagulants/Les-anticoagulants-en-France-Etudes-et-surveillance, 2014.

F. Mentré, F. Pousset, E. Comets, B. Plaud, B. Diquet et al., Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients*, Clinical Pharmacology & Therapeutics, vol.23, issue.1, pp.64-78, 1998.
DOI : 10.1002/cpt196910122

P. Lechat, Les bases pharmacologiques de la th??rapeutique. Analyse pharmacologique du r??sum?? des caract??ristiques d???un produit ( le ?? RCP ??) pour le th??rapeute, Th??rapie, vol.70, issue.5, pp.403-417, 2015.
DOI : 10.2515/therapie/2015025

H. Nessighaoui, H. Géniaux, T. Dantoine, and M. Laroche, M??dicaments et fragilit?? chez les personnes ??g??es. Vers une nouvelle entit????: la fragilit?? pharmacologique???, Th??rapie, vol.71, issue.3, pp.275-284, 2016.
DOI : 10.1016/j.therap.2016.02.021